1. Sun Pharmaceutical: Market Presence and Product Expansion in 2025

Sun Pharmaceutical Industries Ltd. is India’s largest pharmaceutical company and a global leader in generics and specialty medicines. Headquartered in Mumbai, Sun Pharma has built a reputation for delivering high-quality, affordable treatments across more than 100 countries. Its product portfolio spans a wide range of therapeutic categories—from cardiology and psychiatry to oncology and dermatology—making it a go-to partner for hospitals, retail pharmacies, distributors, and international buyers.

As the pharmaceutical industry evolves with new treatment demands, regulatory shifts, and rising global health challenges, knowing what’s inside the Sun Pharma product list for 2025 is more important than ever. Whether you’re a B2B procurement manager, a hospital administrator, or a wholesaler, understanding Sun Pharma’s updated lineup helps ensure better inventory planning, regulatory compliance, and clinical coverage.

Sun Pharma’s 2025 product catalog reflects its commitment to innovation, scale, and strategic expansion into complex generics, biosimilars, and specialty therapies. The company’s pipeline also includes novel delivery systems, biologics, and differentiated products for underserved conditions—ensuring it remains competitive in both emerging and regulated markets.

In this comprehensive guide, we break down the Sun Pharma product list by therapeutic area, highlight key molecules, showcase specialty brands, and provide insights into sourcing, distribution, and global demand.

2. Sun Pharma in 2025 – Company Snapshot

Founded in 1983, Sun Pharmaceutical Industries Ltd. has grown from a small Indian drug manufacturer to one of the world’s most respected pharmaceutical giants. As of 2025, it ranks among the top five generic pharmaceutical companies globally, and remains the number one pharma company in India by revenue and prescription volume.

With a strong emphasis on innovation, operational efficiency, and therapeutic focus, Sun Pharma continues to lead across multiple segments of the pharmaceutical value chain.

2.1 Global Footprint

• Present in over 100 countries with key markets in the US, India, Western Europe, Russia, Brazil, and Southeast Asia
   
• Operates 40+ manufacturing facilities worldwide, many of which are USFDA, WHO-GMP, EU-GMP, and TGA certified
   
• Maintains 8 R&D centers focused on drug delivery systems, biosimilars, and new chemical entities (NCEs)
   

2.2 Therapeutic Focus Areas

Sun Pharma’s product portfolio spans over 30 therapeutic areas, with significant market share in:

• Cardiology and Hypertension
   
• Central Nervous System (CNS) disorders
   
• Oncology and Hematology
   
• Dermatology (Rx and OTC)
   
• Diabetology and Endocrinology
   
• Gastroenterology
   
• Pain Management and Anti-infectives
   

2.3 Revenue Composition (FY 2024–25 Projection)

Segment	Contribution to Revenue (%)
US Generics and Specialty Drugs	31%
India Branded Generics	28%
Emerging Markets	15%
Rest of World (RoW) Markets	12%
API and Contract Manufacturing	9%
Others (Consumer, R&D, Licensing)	5%

 

2.4 R&D and Innovation Strategy

Sun Pharma has significantly expanded its R&D focus to include:

• Specialty medicines like Ilumya, Cequa, and Yonsa
   
• Complex generics and injectables for regulated markets
   
• Biosimilars and antibody-based therapies
   
• Advanced drug delivery platforms (e.g., depot injections, sustained release tablets)
   
• Collaborative partnerships with SPARC (Sun Pharma Advanced Research Company) and global biotech firms
   

2.5 Global Certifications and Regulatory Leadership

Sun Pharma operates best-in-class manufacturing facilities that comply with:

• USFDA (United States Food and Drug Administration)
   
• EMA (European Medicines Agency)
   
• MHRA (UK Medicines and Healthcare Regulatory Agency)
   
• TGA (Australia)
   
• WHO-GMP (World Health Organization – Good Manufacturing Practice)
   

This makes Sun Pharma a preferred source for regulated market tenders, hospital networks, and national health programs.

Sun Pharma’s scale, regulatory readiness, therapeutic depth, and global reputation make its 2025 product list an essential reference point for anyone in the pharmaceutical supply chain—from hospital buyers to wholesale distributors and international sourcing agencies.

3. Sun Pharma Product List by Therapeutic Category

Sun Pharma’s 2025 portfolio features hundreds of molecules across branded, generic, OTC, and specialty formats. Its strength lies not just in the volume of SKUs but in the clinical breadth and global availability of these formulations. The company’s product list covers all major therapeutic segments—allowing hospitals, distributors, and global buyers to source from a single, compliant manufacturer.

Below is a therapeutic-area-wise breakdown of key product groups available in the Sun Pharma product list for 2025:

3.1 Cardiology & Hypertension

Sun Pharma is a market leader in cardiovascular medications, offering both monotherapy and fixed-dose combinations for hypertension, heart failure, and dyslipidemia.

Key Products:

• Amlodipine (calcium channel blocker)
   
• Telmisartan, Olmesartan, Losartan (ARBs)
   
• Atenolol, Bisoprolol (beta blockers)
   
• Rosuvastatin, Atorvastatin, Ezetimibe (statins & lipid-lowering agents)
   
• Ramipril, Enalapril (ACE inhibitors)
   

3.2 Central Nervous System (CNS)

Sun Pharma is among India’s top CNS drug manufacturers, with formulations for depression, epilepsy, schizophrenia, Parkinson’s disease, and neuropathic pain.

Key Products:

• Clonazepam, Alprazolam, Diazepam (anxiolytics)
   
• Escitalopram, Sertraline, Amitriptyline (antidepressants)
   
• Olanzapine, Risperidone, Quetiapine (antipsychotics)
   
• Gabapentin, Pregabalin (neuropathic pain)
   
• Levodopa + Carbidopa (Parkinsonism)
   

3.3 Gastroenterology

Sun Pharma’s GI portfolio is widely prescribed in both primary and hospital care settings, including acid suppression, motility disorders, and hepatic support.

Key Products:

• Pantoprazole, Esomeprazole, Rabeprazole (PPIs)
   
• Domperidone, Itopride, Levosulpiride (prokinetics)
   
• Mesalamine, Sulfasalazine (IBD management)
   
• Lactulose, Rifaximin, Ornithine aspartate (hepatic encephalopathy support)
   

3.4 Anti-Infectives & Antibiotics

Sun Pharma supplies a wide range of antibiotics and antifungals used in hospital settings and retail channels.

Key Products:

• Cefixime, Cefpodoxime, Ceftriaxone (cephalosporins)
   
• Amoxicillin + Clavulanic Acid
   
• Azithromycin, Levofloxacin, Moxifloxacin
   
• Fluconazole, Itraconazole, Voriconazole
   
• Nitrofurantoin, Metronidazole, Linezolid
   

3.5 Dermatology (Rx and OTC)

Sun Pharma is a global leader in dermatology, with a portfolio that includes prescription topical agents, anti-acne treatments, fungal care, and cosmeceuticals.

Key Products:

• Clobetasol, Mometasone, Betamethasone (topical steroids)
   
• Permethrin, Crotamiton, Salicylic acid
   
• Isotretinoin (oral acne treatment)
   
• Antifungal creams: Clotrimazole, Luliconazole, Sertaconazole
   
• OTC skincare under Suncros, Acnelak, Episoft, and Rejuglow brands
   

3.6 Oncology and Chemotherapy

Through partnerships and internal development, Sun Pharma markets oncology injectables and oral formulations for both solid tumors and hematological cancers.

Key Products:

• Docetaxel, Paclitaxel, Doxorubicin (cytotoxic injectables)
   
• Imatinib, Letrozole, Anastrozole, Capecitabine
   
• Targeted therapies under licensing and biosimilar development pipeline
   

3.7 Pain Management & Anti-Inflammatories

From over-the-counter analgesics to hospital-based injectables, Sun Pharma’s pain portfolio addresses both acute and chronic pain syndromes.

Key Products:

• Aceclofenac, Diclofenac, Etodolac, Naproxen
   
• Tramadol, Tapentadol (opioid-class)
   
• Paracetamol in tablet, syrup, IV infusion, and combination formats
   
• Topical sprays, patches, and gels for musculoskeletal pain
   

3.8 Antidiabetics

Sun Pharma’s diabetic care lineup includes oral hypoglycemics and insulin analogs, available in India and emerging export markets.

Key Products:

• Metformin (plain and extended-release)
   
• Glimepiride, Gliclazide, Voglibose
   
• Sitagliptin, Linagliptin, Teneligliptin (DPP-4 inhibitors)
   
• Insulin glargine and lispro (biosimilars under development)
   

3.9 Ophthalmology

Sun Pharma is expanding its ophthalmic portfolio through SPARC and USFDA-approved products in dry eye, inflammation, and glaucoma.

Key Products:

• Cequa (Cyclosporine A) – dry eye disease
   
• Loteprednol, Moxifloxacin eye drops
   
• Artificial tear supplements under OTC lines
   

3.10 OTC and Consumer Wellness Products

Sun Pharma’s OTC division includes dermatology, pain relief, sun care, and nutritional supplements, distributed in India and select international markets.

Key Brands:

• Suncros (sunblock)
   
• Volini (pain relief gel/spray)
   
• Revital H (multivitamin)
   
• Pepfiz, Oxylent (digestive support)
   
• Histac, Teczine (allergy)
   

4. Sun Pharma’s Specialty Drugs and Biologics

In recent years, Sun Pharma has significantly expanded beyond generics to build a high-value specialty portfolio—especially in dermatology, ophthalmology, oncology, and immunology. These drugs target complex, chronic, or underserved conditions that require innovation in formulation, delivery, and global clinical evidence.

Sun’s specialty pipeline and product launches are increasingly supported by Sun Pharma Advanced Research Company (SPARC), which focuses on new molecules and differentiated formulations. By 2025, several of these specialty therapies have achieved strong presence in regulated markets like the US, EU, and Japan, contributing to the company’s global brand equity.

4.1 Dermatology and Autoimmune Segment

Sun Pharma is among the top 5 dermatology companies in the US, thanks to its targeted immunomodulatory treatments and branded topicals.

Flagship Products:

• Ilumya (Tildrakizumab-asmn)
   
  • A biologic used for moderate-to-severe plaque psoriasis
     
  • Administered via subcutaneous injection
     
  • Approved by the USFDA, commercialized in US and select global markets
     
  • Competes with other biologics like Stelara and Cosentyx
     
• Winlevi (Clascoterone)
   
  • A novel anti-androgen topical cream for acne
     
  • Launched in the US and gaining traction in dermatology clinics
     

4.2 Oncology and Hormone Therapy

Sun Pharma’s specialty oncology products offer both targeted oral therapies and injectable cytotoxics, with many launched through licensing partnerships or in-house development.

Key Products:

• Yonsa (Abiraterone Acetate)
   
  • Advanced prostate cancer therapy
     
  • Enhanced bioavailability formulation co-marketed in the US
     
• Tildrakizumab biosimilars & kinase inhibitors (under development for autoimmune and oncology indications)
   
• Oncology injectables like Docetaxel, Oxaliplatin, and Bortezomib are also marketed under the specialty portfolio for hospital use.
   

4.3 Ophthalmology

Through its Cequa brand and expanded ophthalmic pipeline, Sun Pharma is becoming a significant player in eye care innovation, particularly in immunomodulatory therapies for chronic eye diseases.

Key Product:

• Cequa (Cyclosporine ophthalmic solution 0.09%)
   
  • For dry eye disease caused by inflammation
     
  • Uses nanomicellar technology for enhanced absorption
     
  • Approved by the USFDA, now launched in India and EU markets
     

Other ophthalmic pipeline candidates include anti-infectives, anti-inflammatory drops, and formulations for glaucoma and allergic conjunctivitis.

4.4 Complex Generics and Advanced Drug Delivery Systems

Sun Pharma is investing in complex generics that require:

• Liposomal delivery (e.g., Amphotericin B)
   
• Depot injections (for psychiatric and hormonal conditions)
   
• Inhalers and nebulizer solutions (under SPARC pipeline)
   
• Transdermal patches and sustained-release oral tablets
   

These formulations are geared toward hospital settings, chronic disease management, and regulated market differentiation.

4.5 Biosimilars (In Progress)

Sun Pharma has active biosimilar programs in partnership with Biocon, Roche, and in-house R&D, targeting:

• Rheumatoid arthritis
   
• Psoriasis
   
• Breast and colorectal cancer
   
• Insulin analogs
   

Commercial launches are expected in India and select emerging markets before global rollouts.

Sun Pharma’s specialty and biologics division reflects its strategic ambition: to move beyond volume-driven generics and lead in high-margin, clinically differentiated segments. For buyers seeking patent-expired branded therapies, hospital-use biologics, or premium OTC dermatology, this part of the Sun Pharma product list is particularly relevant.

5. Sun Pharma’s Export & B2B Portfolio

Sun Pharma isn’t just India’s largest pharma company—it is also a global pharmaceutical exporter trusted by governments, institutional buyers, hospital networks, and private distributors across more than 100 countries. Its B2B portfolio is strategically built to serve international markets with regulatory-compliant formulations, high-volume APIs, and private-label solutions.

As of 2025, Sun Pharma’s international operations contribute nearly 60% of its total revenues, underscoring its dominance in the global generics, APIs, and specialty drugs markets.

5.1 Global Reach

Sun Pharma has a strong presence in:

• North America (especially the US) – its largest market, with a robust portfolio of ANDA-approved generics and specialty brands
   
• Europe – including Germany, France, UK, and emerging Eastern European markets
   
• South America and LATAM – strategic focus on branded generics
   
• Asia-Pacific and ASEAN – widespread hospital and retail penetration
   
• Africa and Middle East – major supplier to ministries of health, public sector tenders, and WHO distribution programs
   

5.2 Top Exported Products in 2025

Some of the most exported products in the Sun Pharma product list (FDF) include:

• Pantoprazole, Atorvastatin, Metformin, and Amlodipine (chronic therapy anchors)
   
• Gabapentin, Pregabalin, Clonazepam (CNS therapies)
   
• Azithromycin, Amoxicillin-Clavulanic Acid, Cefixime (anti-infectives)
   
• Ilumya, Cequa, Yonsa (specialty and biologics to regulated markets)
   
• Paracetamol (IV, oral, combo) and Diclofenac injectables for hospital use
   

5.3 APIs and Bulk Drugs

Sun Pharma is vertically integrated with API capabilities in-house, which allows for:

• Better pricing control for large-volume buyers
   
• Supply security for regulated and tender-driven demand
   
• API exports for:
   
  • Tamsulosin
     
  • Risperidone
     
  • Clopidogrel
     
  • Telmisartan
     
  • Itraconazole
     

Many APIs are supplied with USDMF, CEP, or WHO prequalification as applicable.

5.4 Contract Manufacturing & Licensing (CDMO)

Sun Pharma partners with:

• Global pharma companies for co-development and tech transfers
   
• Branded marketers in Africa, LATAM, and SEA for private-label or co-marketed generics
   
• Hospital networks and wholesalers for white-label distribution of essential injectables, tablets, and dermatology kits
   

Sun Pharma offers full-cycle B2B services including:

• Formulation development
   
• Regulatory support (filings, CoPP, CoA, DMFs)
   
• Manufacturing and packaging
   
• Global logistics and documentation
   

5.5 Regulatory Documents and Support

For B2B sourcing or government supply programs, Sun Pharma provides:

• Certificate of Pharmaceutical Product (CoPP)
   
• WHO-GMP, EU-GMP, and USFDA site certifications
   
• Batch-wise CoA and Stability data
   
• Dossiers (CTD format) for international tender participation
   
• Multilingual packaging and serialization for export compliance
   

5.6 Ideal for These Buyer Segments

• Distributors and wholesalers serving government health systems
   
• Pharmacy chains and private hospitals in Asia, Africa, and Latin America
   
• NGOs and global public health organizations (e.g., WHO, Global Fund)
   
• Digital health and telemedicine providers seeking branded chronic therapies
   

Sun Pharma’s B2B product infrastructure is backed by global regulatory readiness, scalable logistics, and customized manufacturing, making it one of the most trusted suppliers for buyers worldwide.

6. How to Source Sun Pharma Products (B2B & Institutional Buyers)

For hospitals, pharmacy chains, international distributors, and institutional health programs, sourcing from the Sun Pharma product list offers unmatched advantages in terms of quality, scalability, regulatory compliance, and global fulfillment support. Whether you’re seeking branded generics, APIs, injectables, or specialty formulations, Sun Pharma provides multiple channels and tools to ensure efficient, traceable procurement.

This section outlines the step-by-step process for sourcing Sun Pharma products globally.

6.1 Domestic Procurement (India)

In India, Sun Pharma’s products are distributed through a well-established national network of:

• Stockists and authorized distributors for retail and hospital supply
   
• Direct-to-hospital agreements for institutional buyers
   
• E-distributors and B2B medicine platforms (such as Pharmarack, Netmeds Pro, etc.)
   

Hospitals and pharmacies can contact Sun Pharma’s local territory managers or regional distribution offices to access the latest price list, product catalog, and availability by SKU.

6.2 International Procurement

International buyers—including government agencies, hospitals, and wholesalers—can source from Sun Pharma through:

• Global Sales Divisions (USA, EU, Asia-Pacific, Africa, Latin America)
   
• In-country distributors appointed by Sun Pharma
   
• SPARC & Specialty Division for licensing and specialty products (Ilumya, Cequa, etc.)
   
• Tender and procurement partnerships for WHO, PAHO, and UNICEF orders
   

All exports are backed by the necessary documentation including WHO-GMP, CoPP, DMFs, and country-specific registration dossiers.

6.3 Required Documents for Bulk and Institutional Orders

Buyers typically need to request or submit:

• Product list with trade and international names
   
• MOQ (Minimum Order Quantity) and estimated volumes
   
• Shipping destination & regulatory documentation requirements
   
• Import/export license copies (for international transactions)
   
• Packaging and labeling preferences (multilingual, serialization, etc.)
   

Sun Pharma provides:

• Batch-wise Certificate of Analysis (CoA)
   
• Certificate of Pharmaceutical Product (CoPP)
   
• Stability data and MSDS (if required)
   
• Label customization for different regulatory markets
   

6.4 Contact Channels for B2B Buyers

Buyers can initiate procurement through:

• Official website contact form: www.sunpharma.com/contact
   
• Emailing regional export sales teams (via contact directories or LinkedIn)
   
• B2B pharma trade portals and verified third-party exporters (under contract)
   
• On-ground distribution partners and SPARC licensing representatives
   

6.5 Tips for Successful Long-Term Sourcing

• Establish a supply continuity plan with monthly or quarterly projections
   
• Verify that your supplier is authorized by Sun Pharma to prevent counterfeit sourcing
   
• Ensure the shipment meets import guidelines, such as serialization or cold chain SOPs for injectables
   
• Regularly request updated price lists and regulatory updates (especially for changing tenders)
   

7. Sun Pharma in Tenders and Government Supply

Sun Pharma is not only a leader in commercial sales but also a trusted supplier to government health departments, international NGOs, and global multilateral agencies. Its consistent quality, regulatory approvals, and scale of manufacturing have made it a reliable partner in public sector pharmaceutical procurement, especially for high-volume essential medicines.

From central government schemes in India to WHO and PAHO-led global health programs, Sun Pharma’s product list forms a key part of international tenders, emergency medical supply chains, and mass drug administration programs.

7.1 Domestic Government Supply (India)

In India, Sun Pharma participates in:

• State and Central Government tenders (e.g., CGHS, ESIC, Defense Services, state-run hospitals)
   
• Jan Aushadhi Yojana (PMBJP): Supplying affordable branded generics through public distribution stores
   
• Public sector institutions like AIIMS, Indian Railways, and Central Armed Police Forces (CAPF)
   
• Health missions and immunization campaigns (e.g., NLEM-specified drugs)
   

Popular Sun Pharma products in Indian tenders:

• Pantoprazole, Atorvastatin, Amlodipine, Losartan
   
• Azithromycin, Cefixime, Paracetamol
   
• Rabeprazole + Domperidone, Diclofenac gel, Luliconazole cream
   

7.2 International Tenders & NGO Procurement

Sun Pharma’s exports are actively included in bulk drug tenders floated by:

• World Health Organization (WHO)
   
• Pan American Health Organization (PAHO)
   
• UNICEF, UNDP, UNFPA
   
• The Global Fund to Fight AIDS, Tuberculosis and Malaria
   
• Médecins Sans Frontières (MSF)
   
• Ministries of Health in Africa, Latin America, and Southeast Asia
   

Their products are distributed through both direct participation in international tenders and via authorized local procurement partners.

7.3 Prequalified Products for Global Programs

Several Sun Pharma products meet WHO prequalification standards, making them eligible for use in:

• Maternal and child health kits
   
• HIV/AIDS and TB control programs
   
• Malaria management
   
• Emergency and humanitarian medical supplies
   

Their injectable antibiotics, oral antiretrovirals, pediatric syrups, and topical agents are frequently seen in public health supply kits.

7.4 Formats Offered for Tender Fulfillment

Sun Pharma offers formulations in compliance with tender specifications:

• Tablets (blister or strip pack)
   
• Oral liquids and syrups (HDPE or glass)
   
• Injectables (ampoules, vials, lyophilized)
   
• Topicals (lamitubes, jars, bottles)
   
• Sachets and dispersibles (for pediatric and mass use)
   

They also provide customized secondary packaging, shelf-life certification, and climate zone stability data required by international health ministries and procurement teams.

7.5 Documentation and Tender Readiness

For all tender-based orders, Sun Pharma maintains:

• WHO-GMP / USFDA site certifications
   
• CTD-format dossiers and product registration files
   
• Certificate of Pharmaceutical Product (CoPP)
   
• CoA, MSDS, and zone IV stability data
   
• Serialization and barcode labeling (where required)
   

This makes them fully compliant for participation in e-procurement platforms and fast-moving government contracts.

7.6 Strategic Importance for B2B Buyers

• Reduces risk of supply disruption in mission-critical tenders
   
• Ensures continuity of essential care in remote, under-resourced regions
   
• Enhances credibility when sourcing through publicly audited supply chains
   
• Supports bulk procurement cycles for national immunization and non-communicable disease programs
   

8. FAQs – Sun Pharma Products

Q1. What types of products are included in the Sun Pharma product list for 2025?

The Sun Pharma product list includes a broad range of formulations across key therapeutic areas such as cardiology, CNS, dermatology, gastroenterology, oncology, anti-infectives, ophthalmology, pain management, and diabetes care. It features:

• Branded generics
   
• Specialty drugs (e.g., Ilumya, Cequa)
   
• Biosimilars (in development)
   
• OTC consumer wellness products
   
• Injectables and APIs
   

Q2. Is Sun Pharma a global pharmaceutical supplier?

Yes. Sun Pharma exports to over 100 countries and operates manufacturing facilities approved by USFDA, WHO-GMP, EU-GMP, and other international regulators. It is one of the top five global generic pharmaceutical companies.

Q3. Can hospitals and government institutions directly procure from Sun Pharma?

Yes. Hospitals, state-run health programs, and central government schemes (like CGHS, ESIC, PMBJP) in India routinely procure Sun Pharma products through tenders or institutional distribution agreements. International buyers can work through Sun’s global export teams or authorized B2B distributors.

Q4. Does the Sun Pharma product list include over-the-counter (OTC) and consumer products?

Yes. Sun Pharma has a growing OTC division with popular brands like:

• Volini (pain relief)
   
• Revital H (multivitamin)
   
• Suncros (sun protection)
   
• Teczine (anti-allergy)
  
  These are available across retail and e-commerce platforms in India and select export markets.
   

Q5. How can I request the complete Sun Pharma product catalog for institutional sourcing?

• For corporate and international inquiries
   
• Regional B2B sales representatives or export division offices
   
• Verified supply chain partners or trade portals that represent Sun Pharma
   

You’ll typically need to share:

• Intended market/region
   
• Quantity requirements (MOQ)
   
• Registration or import license (for regulated markets)
   

Q6. Does Sun Pharma manufacture APIs as well as finished formulations?

Yes. Sun Pharma is vertically integrated and manufactures a wide range of Active Pharmaceutical Ingredients (APIs) for internal use and third-party supply. This ensures consistent quality and availability across their global product range.

Q7. Are Sun Pharma’s specialty products like Ilumya and Cequa available outside India?

Yes. Specialty drugs like Ilumya (Tildrakizumab) and Cequa (Cyclosporine A eye drops) are available in the United States, Europe, Japan, and other regulated markets. These products are marketed directly or via licensing and co-marketing partnerships.

9. Conclusion

The Sun Pharma product list for 2025 reflects the company’s continued commitment to scale, quality, and therapeutic innovation. With a portfolio that spans branded generics, APIs, injectables, OTC, biosimilars, and specialty biologics, Sun Pharma is not just India’s pharmaceutical leader—it’s a global standard-bearer in affordable, accessible healthcare.

For hospitals, distributors, government buyers, and international procurement agencies, sourcing from Sun Pharma offers more than just competitive pricing. It ensures:

• Global regulatory compliance with approvals from USFDA, WHO-GMP, EU-GMP, and more
   
• Therapeutic depth across chronic, acute, and specialty care segments
   
• Access to high-volume manufacturing with on-time delivery and batch integrity
   
• Support for tenders and documentation, including CoPP, CoA, stability data, and multilingual packaging
   
• Expansion-ready partnerships in private labeling, CDMO, and co-marketing across regulated and emerging markets
   

As healthcare needs evolve and global supply chains demand resilience and traceability, partnering with a pharma major like Sun Pharma ensures that your sourcing decisions are clinically sound, commercially viable, and future-ready.

If you’re a buyer, clinician, pharmacy chain, NGO, or healthtech leader, understanding the 2025 Sun Pharma product list helps you make informed, strategic, and scalable choices.